戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ion and psychosis with the use of divalproex sodium (valproate).
2 th other medications such as clobazam and/or sodium valproate.
3 development of the child exposed in utero to sodium valproate.
4 e concentrations of the HDACIs vorinostat or sodium valproate.
5  and carbamazepine and greater than those of sodium valproate.
6 tivators in common clinical use--lithium and sodium valproate.
7 ncy over older AEDs namely carbamazepine and sodium valproate.
8 orarginine and histone deacetylase inhibitor sodium valproate.
9 , and typically responsive to treatment with sodium valproate.
10 whether single or multiple administration of sodium valproate, a GABA agonist, would prevent the expr
11                 Some mood stabilizers, e.g., sodium valproate and carbamazepine, are human teratogens
12 ood stabilizers (lithium, carbamazepine, and sodium valproate) and plasma levels of these drugs to fu
13                                              Sodium valproate, benzodiazepines and topiramate were re
14                                              Sodium valproate has been a first-line antiepileptic dru
15             Prescribing of carbamazepine and sodium valproate have declined since 1994 despite being
16 udy compared fosphenytoin, levetiracetam and sodium valproate in adults and children.
17 avioural difficulties in children exposed to sodium valproate in utero.
18 gnancy registers has not only confirmed that sodium valproate is teratogenic but also that it may be
19 tising neurologists had long suspected--that sodium valproate is the most effective drug in the treat
20 dividuals; and Group V, 7 patients receiving sodium valproate monotherapy.
21 OR, 0.32 [95% CI, 0.15-0.67]; P = .003), and sodium valproate (OR, 0.33 [95% CI, 0.15-0.71]; P = .004
22 ated seizures and increased spiking, whereas sodium valproate reduced spiking, mirroring drug respons
23 is undoubtedly a phamacogenetic component to sodium valproate's teratogenic and neurodevelopmental ef
24 disorders in children exposed to monotherapy sodium valproate (VPA) (6/50, 12.0%; aOR 6.05, 95%CI 1.6
25 etiracetam (LEV) 1.00 (0.16 to 1.84) p=0.02; sodium valproate (VPA) 0.74 (0.10 to 1.38) p=0.02; topir
26                                              Sodium valproate (VPA) administered to neonatal mice cau
27 atal exposure to the anti-seizure medication sodium valproate (VPA) is associated with an increased r
28                                              Sodium valproate (VPA) is widely used throughout the wor
29           One proposed adjunctive therapy is sodium valproate (VPA), an anticonvulsant known to promo
30 rbamazepine, lamotrigine, levetiracetam, and sodium valproate) was defined using routinely collected
31             Antibiotics, corticosteroids and sodium valproate were associated with a monophasic disea
32    Therefore, we have examined the effect of sodium valproate, which enhances GABA function, on the d